A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
NCT03020992
Ankylosis, Anterior Uveitis (AU)
Brno, Czechia
View Trial DetailsNCT Number: NCT06591481
The goal of this observational study is to develop and validate an Artificial Intelligence (AI) tool that allows the lesion detection and early diagnosis of axial spondyloarthritis (axSpA) based on Magnetic Resonance Imaging (MRI).
This study will gather MRI scans from axSpA patients and a control group of participants.
Looking for future studies?
Notify Me18 year–44 year
All sexes
Observational
Royal Medical Services, Amman, Jordan
BACKGROUND
The spondyloarthritis (SpA) are a group of chronic inflammatory diseases of autoimmune nature that share common clinical and genetic features, including an association with HLA-B27 antigen. They are among the most common rheumatic diseases with a prevalence of 0.01-2,5%. All of these conditions make the patients to move on a chronic disabling disease.
Patients with SpA can be classified based on their clinical presentation into either predominantly axial SpA (axSpA) or predominantly peripheral SpA. Axial SpA is characterized by primary involvement of the sacroiliac joints (SIJs) and/or the spine, leaading to substantial pain and disability. Until recently, the diagnosis of axSpA relied on detecting of structural changes evocative of sacroiliitis in the SIJs using plain radiography.
The introduction of Magnetic resonance imaging (MRI) for evaluating the SIJs has significantly advanced the recognition of axSpA. MRI can detect early inflammatory processes even in patients who do not yet have structural lesions. Besides, MRI has shown superiority over radiography in detecting structural changes in the SIJs. However, the definition of a "positive MRI" in SpA remains controversial, as both sensitivity and specificity have their limitations. Early diagnosis of SpA has become increasingly important, as treatments are now available, and MRI is emerging as the preferred choice for early diagnosis. A number of randomized controlled trials of anti-tumour necrosis factor agents in ankylosing spondylitis have demonstrated regression of inflammatory lesions in the spine by MRI. Moreover, the role of MRI in the early diagnosis of SpA has become better established, and imaging features of active sacroiliitis by MRI have been defined for axSpA diagnosis.
RATIONALE OF THE STUDY
Despite the current advances in medical imaging and ongoing efforts to improve the classification criteria for axSpA, a high proportion of axSpA patients remain under-diagnosed, leading to delays in diagnosis that can result in a poor prognosis. The volume of unstructured data coming from medical imaging contributes to diagnostic delays. The integration of AI and machine learning technologies in medicine for processing large datasets has led to faster and more accurate analysis, identification of real-world evidence gaps, and the agile generation of evidence to address healthcare providers' and healthcare systems' needs.
This study aims to develop an AI diagnostic tool that combines quantitative MRI data with clinical information to aid in the early diagnosis of axSpA.
OBJECTIVES
Primary objective: To create an AI tool that allows the early diagnosis of axSpA and lesion detection based on MRI.
Secondary objective: Clinical validation of the AI module.
Exploratory objective:
SAMPLE DESCRIPTION
The dataset will consist of 900 MRIs, collected retrospectively. MRI exams will be sourced from patients with active axSpA and from those with inactive or no axSpA (control group). The control-to-case ratio will be set at 40/60, allowing the algorithm to learn from both subsets without favoring one group over the other. Since AI can more easily characterize normality than pathology, the proportion of non-axSpA and normal MRIs can be lower (approximately 40%) compared to the 60% allocated to axSpA MRIs. Among the active axSpA group, the distribution of MRIs across classification categories (oedema, ankylosing, erosion, and fat metaplasia) should be as balanced as possible, ideally with 25% assigned to each category. Each MRI does not necessarily come from a different patient, as they may represent different time points for the same individual.
ANALYSIS PLAN
All the images received from sites will be checked by imaging technicians to guarantee the homogeneity of the data
A centralized radiological review of the MRI images will be conducted by senior MSK expert radiologists. Each case will be evaluated by two radiologists. If there is a disagreement between the two, a third radiologist will review the case.
The radiologists will classify the MRIs into the study's various classes and cohorts based on the ASAS criteria for defining active sacroiliitis on MRI for the classification of axial spondyloarthritis. All radiologists involved in the project will receive training to detect lesions according to the ASAS criteria, and this training will be documented and stored in the study's repository.
The imaging technicians will delineate the lesions detected by the MSK expert radiologists to generate a 3D volume. This will be then reviewed by the MSK expert radiologist.
To obtain further information of the lesions labeled, a texture analysis will be performed to quantify several features related to the heterogeneity of the tissue that can be considered as an indicator of the pathological process. The radiomic panel will be based on the following features:
Using the MRIs collected together with the imaging biomarkers and other clinical information available, the data scientists will create an AI-based model that will provide a probability score of axSpA for each subject.
To create the AI module, the database will be divided in three non-balanced sub datasets (training, validation and test). The bigger dataset of images will be used for training the module. After the training phase, the validation database will be used to check if the classification is well done or the model should be trained again.
Training: Set of cases used to fit the model during the training process. These will be the cases the model will use to tune its weights, i.e. the cases that the model will use to "learn".
Validation: Set of cases used to evaluate the model during the training process, therefore, are not used to tune the model weights. This dataset is used for three main purposes:
Test: A separate set, not used for training or validation, will be used for the final model evaluation.
In this study, MRI exams will be obtained from various scanners and institutions. Therefore, the acquisition protocols and reconstruction techniques may vary between scanners. To address this, preprocessing techniques will be applied to standardise the images across different scanners.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Active axSpA patients group:
Inclusion criteria
for Control group:
Exclusion criteria
Time frame: From diagnosis until sample completion (an average of 2 years)
The metric used for parameter optimization and model selection will be the area under the curve (AUC) for balanced dataset.
Time frame: From diagnosis until sample completion (an average of 2 years)
In case of unbalanced dataset, F1 score will be used for parameter optimization and model selection.
Time frame: From diagnosis until sample completion (an average of 2 years)
Time frame: From diagnosis until sample completion (an average of 2 years)
Time frame: From diagnosis until sample completion (an average of 2 years)
Time frame: From diagnosis until sample completion (an average of 2 years)
Ángel Alberich Bayarri
Industry
Retrospective Case-control Study for the Development of an Artificial Intelligence (AI)-Based Tool of Lesion Detection Based on Magnetic Resonance Imaging (MRI) and Clinical Variables for Early Diagnosis of Axial Spondyloarthritis (axSpA)
Acronym: InnovaDetect
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03020992
Ankylosis, Anterior Uveitis (AU)
Brno, Czechia
View Trial DetailsNCT03322618
Ankylosing Spondylitis (AS), Ankylosis
Marseille, France
View Trial DetailsNCT07430189
Ankylosis, Arthritis
Balıkesir, Turkey (Türkiye)
View Trial DetailsNCT06699238
Aerobic Exercise, Ankylosis
Ankara, Turkey (Türkiye)
View Trial Details